Background & Aims: This observational retrospective study aimed at evaluating the effects of one-year administration of homotaurine (tramiprosate) in a sample patients presenting with symptoms of mild cognitive impairment. Methods: Patient’s demographic data and medical history are reported. Each patient performed brain imaging and neuropsychological assessment to reach the diagnosis. Each patient assumed 100 mg total dose of homotaurine/day. The evolution of the cognitive decline over time was evaluated my means of the Mini Mental State Examination (MMSE). Results: 245 patients from 28 different centres in Italy were recruited. Significant improvements from baseline expressed as mean MMSE total score were observed in patients with aMCI at months 8 and 12 (p < 0.0001), and in those with mMCI at month 4 (p < 0.05). Conclusions: Administration of homotaurine revealed beneficial effects in our sample population of MCI patients. Our results indicate clearly that homotaurine may well be considered as a potential symptomatic treatment for cognitive symptoms. Further research is however needed to clarify whether this compound could influence the progression of cognitive decline.
Effect of homotaurine in patients with cognitive impairment: Results from an Italian observational retrospective study
Koch G.;Vitale E.;Codemo A.;Poli S.;Ruggiero R.;
2018
Abstract
Background & Aims: This observational retrospective study aimed at evaluating the effects of one-year administration of homotaurine (tramiprosate) in a sample patients presenting with symptoms of mild cognitive impairment. Methods: Patient’s demographic data and medical history are reported. Each patient performed brain imaging and neuropsychological assessment to reach the diagnosis. Each patient assumed 100 mg total dose of homotaurine/day. The evolution of the cognitive decline over time was evaluated my means of the Mini Mental State Examination (MMSE). Results: 245 patients from 28 different centres in Italy were recruited. Significant improvements from baseline expressed as mean MMSE total score were observed in patients with aMCI at months 8 and 12 (p < 0.0001), and in those with mMCI at month 4 (p < 0.05). Conclusions: Administration of homotaurine revealed beneficial effects in our sample population of MCI patients. Our results indicate clearly that homotaurine may well be considered as a potential symptomatic treatment for cognitive symptoms. Further research is however needed to clarify whether this compound could influence the progression of cognitive decline.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
